C4 Therapeutics (CCCC) Short-term Investments (2020 - 2026)

C4 Therapeutics has reported Short-term Investments for 7 years, with the latest figure at $174.4 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 6.47% year-over-year to $174.4 million; the trailing twelve-month figure through Mar 2026 stood at $174.4 million (up 6.47% YoY), and the FY2025 full-year result was $173.9 million, down 8.17% from the prior year.
• Short-term Investments for Q1 2026 stood at $174.4 million, roughly flat from $173.9 million in the prior quarter.
• The five-year high for Short-term Investments was $264.1 million in Q3 2022, with the low at $127.1 million in Q4 2023.
• Average Short-term Investments over 5 years is $191.7 million, with a median of $189.4 million recorded in 2024.
• Year-over-year, Short-term Investments tumbled 48.42% in 2023 and surged 49.03% in 2024.
• Tracing CCCC's Short-term Investments over 5 years: stood at $246.4 million in 2022, then plunged by 48.42% to $127.1 million in 2023, then jumped by 49.03% to $189.4 million in 2024, then decreased by 8.17% to $173.9 million in 2025, then climbed by 0.27% to $174.4 million in 2026.
• The last three Short-term Investments figures came in at $174.4 million (Q1 2026), $173.9 million (Q4 2025), and $133.1 million (Q3 2025), per Business Quant data.

Peer Comparison